利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.016 秒)

    USE OF VITAMIN K TO DECREASE ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION
    1.
    发明公开
    USE OF VITAMIN K TO DECREASE ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION 审中-公开
    维生素K用于减少ALLOTRANSPLANTATVERSAGEN和患者的死亡率后器官移植用途

    公开(公告)号：EP2854788A1

    公开(公告)日：2015-04-08

    申请号：EP13729628.1

    申请日：2013-06-04

    申请人： VitaK B.V.

    发明人： VERMEER, Cornelis ,  DE BORST, Martin

    IPC分类号： A61K31/122 ,  A61P37/06

    CPC分类号： G01N33/68 ,  A61K31/122 ,  A61K31/593 ,  A61K45/06 ,  G01N2333/47 ,  G01N2440/10 ,  G01N2800/52 ,  A61K2300/00

    摘要： Circulating uncarboxylated matrix Gla-protein (ucMGP), in particular desphospho-ucMGP, is provided as a prognostic biomarker for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. A diagnostic tool is provided to monitor vitamin K status in such patients, i.e. the level of uncarboxylated species of extra-hepatic vitamin K-dependent proteins. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the treatment of such patients resulting in decreased allograft failure and improved patient survival.

    摘要翻译： 循环未羧化的骨钙基质蛋白（ucMGP），特别是desphospho-ucMGP，是谁收到器官移植，谁是下免疫抑制药物的患者提供用于移植失败和死亡的预后标志物。 一种诊断工具被提供给监测患者维生素K状态检查，即 肝外维生素K依赖性蛋白质的未羧基化的物种的水平。 各种形式和推荐的维生素K的剂量，任选地与维生素D和/或其他免疫抑制药物的组合，提供了最优化的寻求减少同种异体移植物衰竭和提高患者存活率得到的患者的治疗。

    NEW BIOMARKERS TO ESTIMATE THE RISK OF ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION
    3.
    发明公开
    NEW BIOMARKERS TO ESTIMATE THE RISK OF ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION 审中-公开
    新的生物标志物估算患者ALLOTRANSPLANTATVERSAGEN和售后服务器官移植死亡风险

    公开(公告)号：EP2856152A1

    公开(公告)日：2015-04-08

    申请号：EP13729629.9

    申请日：2013-06-04

    申请人： VitaK B.V.

    发明人： VERMEER, Cornelis ,  DE BORST, Martin

    IPC分类号： G01N33/49 ,  A61P37/06

    CPC分类号： G01N33/68 ,  A61K31/122 ,  A61K31/593 ,  A61K45/06 ,  G01N2333/47 ,  G01N2440/10 ,  G01N2800/52 ,  A61K2300/00

    摘要： Circulating uncarboxylated matrix Gla-protein (ucMGP), in particular desphospho-ucMGP, is provided as a prognostic biomarker for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. A diagnostic tool is provided to monitor vitamin K status in such patients, i.e. the level of uncarboxylated species of extra-hepatic vitamin K-dependent proteins. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the treatment of such patients resulting in decreased allograft failure and improved patient survival.

    摘要翻译： 循环未羧化的骨钙基质蛋白（ucMGP），特别是desphospho-ucMGP，是谁收到器官移植，谁是下免疫抑制药物的患者提供用于移植失败和死亡的预后标志物。 一种诊断工具被提供给监测患者维生素K状态检查，即 肝外维生素K依赖性蛋白质的未羧基化的物种的水平。 各种形式和推荐的维生素K的剂量，任选地与维生素D和/或其他免疫抑制药物的组合，提供了最优化的寻求减少同种异体移植物衰竭和提高患者存活率得到的患者的治疗。

    Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation
    4.
    发明公开
    Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation 审中-公开
    使用维生素K以减少Allotransplantatversagens和患者死亡器官移植后

    公开(公告)号：EP2671574A1

    公开(公告)日：2013-12-11

    申请号：EP12170756.6

    申请日：2012-06-04

    申请人： VitaK B.V.

    发明人： Vermeer, Cornelis ,  De Borst, Martin Hendrik

    IPC分类号： A61K31/122 ,  G01N33/49 ,  A61P37/06

    CPC分类号： G01N33/68 ,  A61K31/122 ,  A61K31/593 ,  A61K45/06 ,  G01N2333/47 ,  G01N2440/10 ,  G01N2800/52 ,  A61K2300/00

    摘要： Circulating uncarboxylated matrix Gla-protein (ucMGP), in particular desphospho-ucMGP, is provided as a prognostic biomarker for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. A diagnostic tool is provided to monitor vitamin K status in such patients, i.e. the level of uncarboxylated species of extra-hepatic vitamin K-dependent proteins. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the treatment of such patients resulting in decreased allograft failure and improved patient survival.

    摘要翻译： 循环未羧化的骨钙基质蛋白（ucMGP），特别是desphospho-ucMGP，是谁收到器官移植，谁是下免疫抑制药物的患者提供用于移植失败和死亡的预后标志物。 一种诊断工具被提供给监测患者维生素K状态检查，即 肝外维生素K依赖性蛋白质的未羧基化的物种的水平。 各种形式和推荐的维生素K的剂量，任选地与维生素D和/或其他免疫抑制药物的组合，提供了最优化的寻求减少同种异体移植物衰竭和提高患者存活率得到的患者的治疗。

    Compositions for treating or preventing cardiovascular disease
    5.
    发明公开
    Compositions for treating or preventing cardiovascular disease 有权
    Verwendung von维生素K，um die Verkalkung derBlutgefässerückgängigzu machen

    公开(公告)号：EP1728507A1

    公开(公告)日：2006-12-06

    申请号：EP06076172.3

    申请日：2006-06-06

    申请人： Vitak B.V.

    发明人： Vermeer, Cees

    IPC分类号： A61K31/122 ,  A61K31/593 ,  A23L1/302 ,  A23L1/303 ,  A61P9/10

    CPC分类号： A61K31/593 ,  A23L33/15 ,  A23L33/155 ,  A23V2002/00 ,  A61K31/122 ,  A61K2300/00 ,  A23V2250/71 ,  A23V2200/326

    摘要： Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

    摘要翻译： 维生素K对抗心血管疾病有效，例如通常与衰老过程有关的动脉弹性的降低。 可以使用包含维生素K的药物组合物或营养制剂来对抗动脉的年龄相关硬化，其后果是肺充血，高血压，左心室肥大，充血性（右侧）心力衰竭，左侧或左心室 失败，慢性心力衰竭，心绞痛，心肌梗塞，Mönckeberg的硬化症和中风。 在各种实施方案中，还可以使用维生素K来减少或逆转预先存在的心血管疾病例如动脉硬化的血管钙化。

    Diagnostic assay for human matrix gla-protein and its use as a biomarker
    6.
    发明公开
    Diagnostic assay for human matrix gla-protein and its use as a biomarker 有权
    人类基质gla蛋白诊断测定及其作为生物标志物的用途

    公开(公告)号：EP1591791A3

    公开(公告)日：2005-11-16

    申请号：EP05075994.3

    申请日：2005-04-26

    申请人： Vitak B.V.

    发明人： Vermeer, Cornelis, c/o VitaK B.V.

    IPC分类号： G01N33/68

    CPC分类号： G01N33/564 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C07K2317/33 ,  G01N33/57488 ,  G01N33/6887 ,  G01N2333/47 ,  G01N2333/515 ,  G01N2800/105 ,  G01N2800/32 ,  G01N2800/323

    摘要： The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.

    摘要翻译： 本发明包括用于检测和测定人血清样品中MGP的诊断测定法，其包括使用一种或多种特异性识别人类基质Gla-蛋白质上和/或构象表位的抗体，优选单克隆抗体。 提供了使用MGP相关抗原作为某些疾病的生物标志物的方法，例如动脉粥样硬化和其他血管疾病以及肿瘤发展中的血管生成/新生。 描述了用于测定的IgG类单克隆抗体，其在本文中定义为mAb3-15，mAb35-49 [Glu]，mAb35-49 [Gla]，mAb35-53 [Glu]和mAb35-53 [Gla] 。 还公开了用于测量人血清样品中的MGP的多克隆抗体和方法。

    ISOPRENYL DERIVATIVES AND THEIR USE IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS AND CARDIOVASCULAR CALCIFICATION
    7.
    发明公开
    ISOPRENYL DERIVATIVES AND THEIR USE IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS AND CARDIOVASCULAR CALCIFICATION 审中-公开
    异戊二烯衍生物及其在治疗和使用预防心脏钙化或骨质疏松症

    公开(公告)号：EP1414387A2

    公开(公告)日：2004-05-06

    申请号：EP02794586.4

    申请日：2002-08-05

    申请人： Vitak B.V.

    发明人： Vermeer, CeerVitak BV

    IPC分类号： A61K6/00

    CPC分类号： C07C50/06 ,  C07C50/14 ,  C07C69/007 ,  C07C69/616 ,  C07C69/675 ,  C07C69/78

    摘要： A non-toxic biologically active compound is provided having the following general formula (I), wherein n is an integer from 1 to 14, preferably from 2 to 4, and R is an organic moiety, preferably a group different from but structurally substantially similar to 2-methyl naphthoquinone, or a group P-C(R1)-P, where each P stands for a -PO(OH)2 group and R1 is a (poly)isoprenyl group, hydroxy, halogen (preferably chloro or bromo), or hydrogen, or a pharmaceutically acceptable derivative thereof. These compounds are useful for the treatment or prevention of certain disorders in a mammal, especially a human being, for example postmenopausal loss of bone in women, juvenile or senile osteoporosis in men and women, cardiovascular calcification and other ectopic calcifications.

    EPIDERMAL SKIN HEALTH
    9.
    发明公开
    EPIDERMAL SKIN HEALTH 审中-公开
    表皮健康

    公开(公告)号：EP3250180A2

    公开(公告)日：2017-12-06

    申请号：EP16701782.1

    申请日：2016-01-27

    申请人： VitaK B.V.

    发明人： VERMEER, Cornelis

    IPC分类号： A61K8/64 ,  A61K8/67 ,  A61Q19/00 ,  A61Q19/08

    CPC分类号： A61Q19/08 ,  A61K8/64 ,  A61K8/67 ,  A61Q19/00

    摘要： The present invention provides methods and compositions for treating or preventing skin cancer, in particular melanoma, parakeratosis, improving the skin integrity, the skin barrier function and/or decreasing skin ageing in a mammalian subject, preferably a human subject, the method comprising applying vitamin K1, vitamin K2, Matrix Gla-Protein (MGP) or at least one bioactive peptide derived from MGP in an effective amount to the skin. Preferably, the vitamin K comprises at least one of the long-chain menaquinones MK-7 through MK-10. Preferably, the MGP-derived peptides contain the uncarboxylated Gla-domain of human MGP.